Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Health expenditure efficiency: implications for pharmaceutical marketing

Health expenditure efficiency: implications for pharmaceutical marketing Purpose – The purpose of this paper is to consider the efficiency of US healthcare in an international context. The paper emphasizes the concept of efficiency and explores implications for pharmaceutical marketing. Design/methodology/approach – Literature review, economic theory, secondary data and bivariate regression were used to describe and evaluate US healthcare spending and pharmaceutical marketing. Findings – US healthcare spending is inordinately high as a share of gross domestic product within developed countries and this is associated with a relatively high share of private finance. But public sector finance is displacing private payment and this trend is especially pronounced for pharmaceuticals. Public finance combined with fiscal pressure can be expected to curb use of pharmaceutical detailing and other forms of marketing. The limits of affordability are not well assessed and socio‐economic institutions to facilitate decisions about present and future costs have yet to evolve. Originality/value – This paper provides a macro perspective for healthcare finance and the marketing of pharmaceuticals. It pioneers analysis of economics and international healthcare systems integrated with the foundations of demand for pharmaceutical marketing. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png International Journal of Pharmaceutical and Healthcare Marketing Emerald Publishing

Health expenditure efficiency: implications for pharmaceutical marketing

Download PDF
17 pages

Loading next page...
 
/lp/emerald-publishing/health-expenditure-efficiency-implications-for-pharmaceutical-vjoKZ0BOFB
Publisher
Emerald Publishing
Copyright
Copyright © 2011 Emerald Group Publishing Limited. All rights reserved.
ISSN
1750-6123
DOI
10.1108/17506121111149235
Publisher site
See Article on Publisher Site

Abstract

Purpose – The purpose of this paper is to consider the efficiency of US healthcare in an international context. The paper emphasizes the concept of efficiency and explores implications for pharmaceutical marketing. Design/methodology/approach – Literature review, economic theory, secondary data and bivariate regression were used to describe and evaluate US healthcare spending and pharmaceutical marketing. Findings – US healthcare spending is inordinately high as a share of gross domestic product within developed countries and this is associated with a relatively high share of private finance. But public sector finance is displacing private payment and this trend is especially pronounced for pharmaceuticals. Public finance combined with fiscal pressure can be expected to curb use of pharmaceutical detailing and other forms of marketing. The limits of affordability are not well assessed and socio‐economic institutions to facilitate decisions about present and future costs have yet to evolve. Originality/value – This paper provides a macro perspective for healthcare finance and the marketing of pharmaceuticals. It pioneers analysis of economics and international healthcare systems integrated with the foundations of demand for pharmaceutical marketing.

Journal

International Journal of Pharmaceutical and Healthcare Marketing – Emerald Publishing

Published: Jun 28, 2011

Keywords: National health expenditures; Efficiency; Pharmaceuticals industry; Marketing; Advertising; United States of America

References

  • Economic content in medical journal advertisements for medical devices and prescription drugs
    Ackerly, D.C.; Glickman, S.; Schulman, K.
  • Electronic detailing (e‐detailing) of pharmaceuticals to physicians: a review
    Alkhateeb, F.; Doucette, W.
  • Characteristics of physicians who see pharmaceutical sales representatives
    Alkhateeb, F.; Khanfar, N.; Clauson, K.
  • Do health insurers possess monopsony power in the hospital services industry?
    Bates, L.; Santerre, R.
  • Relative financial burden of health care expenditures
    Bennett, K.; Powell, M.; Probst, J.
  • Pharmaceuticals in US health care determinants of quantity and price
    Berndt, E.
  • Direct to consumer advertising in pharmaceutical markets
    Brekke, K.; Kuhn, M.
  • Employment by industry, occupation, and percent distribution, 2008 and projected 2018
    Bureau of Labor Statistics
  • Consumer price index – all urban consumers – all items
    Bureau of Labor Statistics
  • Characteristics of patients receiving pharmaceutical samples and association between sample receipt and out‐of‐pocket prescription costs
    Caleb, A.; Zhang, J.; Basu, A.
  • Physicians, pharmaceutical sales representatives, and the cost of prescribing
    Caudill, T.; Johnson, M.; Rich, E.; McKinney, W.
  • National nursing home survey
    Center for Disease Control and Prevention, Long Term Care Statistics Branch
  • National health expenditure projections 2009‐2019
    CMS
  • Updated national health expenditure projections 2009‐2019
    CMS
  • Theory of Monopolistic Competition
    Chamberlain, E.
  • Nonbranded drugs are expected to continue their strong growth. But could the dearth of their new branded rivals cause the sector to hit a wall?
    Chemical Industry News and Intelligence
  • Pluralism, public choice, and the state in the emerging paradigm of health systems
    Chernichovsky, D.
  • Physician and drug representatives: exploring the dynamics of the relationship
    Chimonas, S.; Brennan, T.; Rothman, D.
  • The long‐term outlook for health care spending
    Congressional Budget Office
  • How the recovery act's federal coordinating council paved the way for the patient‐centered outcomes research institute
    Conway, P.
  • Characteristics of recipients of free prescription drug samples: a nationally representative analysis
    Cutrona, S.; Woolhandler, S.; Lasser, K.; Bor, D.; McCormick, D.; Himmelstein, D.
  • The effects of pharmaceutical marketing and promotion on adverse drug events and regulation
    David, G.; Markowitz, S.; Richards‐Shubik, S.
  • The state of public research on over‐the‐counter drug advertising
    DeLorme, D.; Huh, J.; Reid, L.; An, S.
  • A decade of direct‐to‐consumer advertising of prescription drugs
    Donohue, J.; Cevasco, M.; Rosenthal, M.
  • Effects of pharmaceutical promotion on adherence to the treatment of guidelines for depression
    Donohue, J.; Berndt, E.; Rosenthal, M.; Epstein, A.; Frank, R.
  • The Economic Evolution of American Health Care: From Marcus Welby to Managed Care
    Dranove, D.
  • Malmquist productivity indexes and fisher ideal indexes
    Fare, R.; Grosskopf, S.
  • Prescribers and pharmaceutical representatives: why are we still meeting?
    Fischer, M.; Keough, M.E.; Baril, J.; Saccoccio, L.; Mazor, K.; Ladd, E.; von Worley, A.; Gurwitz, J.
  • The sustainability of health spending growth
    Follette, G.; Sheiner, L.
  • The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States
    Gagnon, M.; Lexchin, J.
  • Is American health care uniquely inefficient
    Garber, A.; Skinner, J.
  • Direct‐to‐consumer prescription advertising in Canada: permission by default?
    Garnder, D.; Mintzes, B.; Ostry, A.
  • The big squeeze
    Goldberg, M.; Davenport, B.; Morellito, T.
  • The evaluation of educational and economic effects of life expectation by linear regression analysis
    Hanada, K.
  • Solving the accountable care conundrum
    Harris, J.; Grauman, D.; Hemnani, R.
  • Health spending growth at a historic low in 2008
    Hartman, M.; Martin, A.; Nuccio, O.; Catlin, A.; The National Health Expenditure Accounts Team
  • Effect of drug sample removal on prescribing in a family practice clinic
    Hartung, D.; Evans, D.; Haxby, D.; Draemer, D.; Andeen, G.; Fagnan, L.
  • Pharmaceutical industry marketing and influence
    Haxby, D.
  • Health statistics
    Health Systems Trust
  • Efficiency and justice revisited
    Holler, M.; Leroch, M.
  • Drug reps and the academic medical center: a case for management rather than prohibition
    Huddle, T.
  • The pitfalls of deducing ethics from behavioral economics: why the association of American medical colleges in wrong about pharmaceutical detailing
    Huddle, T.
  • Product sampling in a new era of cost efficiencies
    IMS Health
  • Total US promotional spend by type, 2009
    IMS Health
  • ZRG partners life science hiring index edges up globally in Q 3, but mixed signals appear
    Investment Weekly News
  • Implications of behavioral decision theory for health marketing
    Jones, S.
  • Bias free measurement of technical efficiency
    Kalirajan, K.; Bhide, S.
  • The endogenous modeling of the effect of direct‐to‐consumer advertising in prescription drugs
    Kalyanaram, G.
  • Product differentiation, competition and regulation of new drugs: the case of statins in four European countries
    Kanavos, P.; Font, J.C.; McGuire, A.
  • Insurance exchanges under health reform: six design issues for the states
    Kingsdale, J.; Bertko, J.
  • Open access and dynamic efficiency
    Klumpp, T.; Su, X.
  • Social Marketing
    Kotler, P.; Roberto, N.; Lee, N.
  • Income disparity, inequality aversion and the design of the healthcare system
    Leach, J.
  • Pharmaceutical price discrimination and social welfare
    Lichtenberg, F.
  • What will it take to make cost‐effectiveness analysis acceptable in the United States?
    Luce, B.
  • Expect big pharma layoffs of 2007 to continue: report
    McGuire, S.
  • How does direct‐to‐consumer advertising (DCTA) affect prescribing?
    Mintjes, B.; Barer, M.; Kravitz, R.; Bassett, K.; Lexchin, J.; Kazanjian, A.; Evans, R.G.; Pan, R.; Marion, S.A.
  • Information as advertising in the market for hospital care
    Montefiori, M.
  • The Danish health care system: it ain't broke. So don't fix it
    Mooney, G.
  • Health Insurance
    Morrisey, M.
  • 30 years of pharmaceutical cost‐utility analyses: growth, diversity and methodological improvement
    Neumann, P.; Fang, C.; Cohen, J.
  • Medical‐care expenditures: a cross‐national survey
    Newhouse, J.
  • OECD health data‐selected data
    Organization for Economic Co‐operation and Development
  • Taxation, health insurance, and market failure in the medical economy
    Pauly, M.
  • The economics of inequality in health: a bibliography
    Pereira, J.
  • The relationship between emotional intelligence and customer orientation for pharmaceutical salespeople
    Pettijohn, C.; Rozell, E.; Newman, A.
  • Advertising and competition in the ethical pharmaceutical industry: the case of antihypertensive drugs
    Rizzo, J.
  • Limits to rationality: economics, economists and priority setting
    Robinson, R.
  • Consumer driven health care: promise and performance
    Robinson, J.; Ginsburg, P.
  • Promotion of prescription drugs to consumers
    Rosenthal, M.; Berndt, E.; Donohue, J.; Frank, R.; Epstein, A.
  • Pharmaceutical marketing: medical and industry biases
    Rubin, P.
  • Industrial Market Structure and Economic Market Performance
    Scherer, F.; Ross, D.
  • In chronic condition: experiences of patients with complex health care needs, in eight countries
    Schoen, C.; Osborn, R.; How, S.; Doty, M.; Peugh, J.
  • Marketing Theory: Classic and Contemporary Readings
    Sheth, J.; Garrett, D.
  • Physicians' perceptions and uses of commercial drug information sources: an examination of pharmaceutical marketing to physicians
    Spiller, L.; Wymer, W.
  • Is there monopsony in the labor market? Evidence from a natural experiment
    Staiger, D.; Spetz, J.; Phibbs, C.
  • The Social Transformation of American Medicine
    Starr, P.
  • Foul weather friends: big business and health care reform in the 1990s in historical perspective
    Swenson, P.; Greer, S.
  • Pass the pills
    The Economist
  • Conceptual issues in the measurement of economic and productive efficiencies
    Tisdell, C.A.
  • Health spending projections through 2019: the recessions impact continues
    Truffer, C.; Keehan, S.; Smith, S.; Cylus, J.; Sisko, A.; Poisal, J.; Lizonitz, J.; Clemens, M.K.
  • Statistical Abstract of the United States: 2011
    US Bureau of the Census
  • Personal use of drug samples by physicians and office staff
    Westfall, J.; McCabe, J.; Nicholas, R.
  • Drug firms spending on consumer ads fell 8% in '08, a rare marketing pullback
    Winstein, K.; Vranica, S.
  • World Development Report: Development and Climate Change
    World Bank